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INTRODUCTION
Optimizing G protein-coupled receptor (GPCR) ligand bias is a promising drug discovery strategy that may offer the ability to improve clinical efficacy by selectively manipulating signalling of the target receptor. This is founded on observations that individual GPCRs can signal through multiple cellular effector pathways and that some ligands can preferentially activate certain responses over others. Ligand bias has been rationalized in terms of each ligand uniquely changing the conformational equilibrium of the receptor population, and thus its signalling repertoire, by virtue of how the ligand interacts with the binding site (Kenakin, 2007; Vaidehi & Kenakin, 2010 ).
The µ-opioid receptor (MOR) is one example where opportunities for using ligand bias to improve pharmacotherapeutic response window are beginning to be exploited . MOR is a primary target of opiates, such as morphine, which represent the most powerful analgesics available.
Whilst highly efficacious for the treatment of pain, opiate usage is limited by side effects that include constipation and respiratory depression. MOR can signal through both inhibitory G protein G αi/o , and β-arrestin. Based on observations in β-arrestin2 knockout mice, where the activity of morphine is enhanced with an alleviated side-effect profile, it was proposed that the β-arrestin branch of MOR signalling mediates the adverse effects of opiate therapy, whilst the beneficial effects are mediated through G protein (Bohn et al., 1999; Raehal et al., 2005) . Therefore, better MOR drugs might be developed by optimizing biased ligands that preferentially activate G αi/o . Indeed, the G protein-biased MOR agonist TRV130 has been identified, and shows a promising clinical profile (DeWire et al.,
2013;Soergel et al., 2014;Viscusi et al., 2016). Recently another G protein-biased MOR agonist with
reduced side-effects, PZM21, has also been described (Manglik et al., 2016) .
It remains elusive precisely how ligand binding site interactions influence receptor conformational dynamics and hence biased signalling. Understanding which receptor regions control effector coupling and which residues ligands interact with to selectively regulate this coupling offers huge M A N U S C R I P T
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potential for the discovery of biased ligands. This might allow us to predict interaction patterns that govern ligand bias and subsequently develop medicinal chemistry strategies that specifically target these residues. Clues about the nature of receptor conformational rearrangements come from biophysical studies that have identified differential movement of key residues when comparing the binding of biased and non-biased ligands (Liu et al., 2012; Rahmeh et al., 2012) . In agreement, GPCR crystallography also suggests that biased ligands bind with different patterns to non-biased ligands (Wacker et al., 2013; Warne et al., 2012) . Receptor mutagenesis is an alternative approach that has identified regions within a number of GPCRs that can control how they signal in a ligand-specific manner (Bock et we identified key residues within the MOR binding pocket predicted to influence ligand recognition and signalling. In this study, we investigated the effect of mutating these residues on the generation of ligand bias. At wildtype and mutant MOR, the pharmacology of a panel of ligands was characterized for both the G protein and β-arrestin2 branches of signalling and the effect of the mutation on signal bias was quantified. We observe some distinct patterns of ligand-specific effects across the mutant receptors, enabling us to build up a picture of how ligand binding interactions at given residues can translate to a given pharmacological profile.
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MATERIALS & METHODS

Materials
Cell culture materials were from Invitrogen, and DNA was synthesized by ThermoFisher. Restriction endonucleases were purchased from New England Biolabs. Assay plates were from Greiner. cAMP femto HTRF (homogenous time-resolved fluorescence) assay kits were from Cisbio. β-arrestin2
PathHunter detection reagents were from DiscoverX. [15, H]diprenorphine (specific activity 25.8
Ci/mmol) and Uni-filter GF/B plates were from Perkin Elmer. DAMGO (D-Ala 2 ,N-MePhe 4 ,Gly-ol]-enkephalin), morphine, endomorphin-1, endomorphin-2, met-enkephalin, naloxone, isoprenaline hydrochloride, and IBMX (3-isobutyl-1-methylxanthine) were from Sigma-Aldrich. Pfizer standard-1
described previously (Jacobson et al., 1989) , was synthesized at Pfizer
Mutagenesis
The coding region of human MOR was amplified from an existing construct by PCR, removing the stop codon, inserting two C-terminal bases to maintain reading frame and introducing a 5' NheI site and 3' HindIII site. Primers used were MOR1_NheI_f 5'-GCTAGCCACCATGGACAGCAGCGCTGC-3' and MOR1_HindIII_r 5'-AAGCTTGAGGGCAACGGAGCAGTTTCTGCTTCC-3' (Integrated DNA Technologies, Coralville, USA). The product was ligated into pCMV-ProLink (DiscoverX, Birmingham, UK.) via digestion with NheI and HindIII, resulting in a 3'-tagged ProLink-tagged hMOR construct (pCMVProLink_hMOR). Subsequently, similar fragments containing the point mutations W320A (tgg gcg) and Y328F (tac ttc) ( Figure 1 ) were synthesized and sub-cloned in the same way.
Cell culture and transfection
For consistency, the same set of cell lines individually expressing each MOR species were used across all experiments. These were stable pools of HEK293 cells expressing both human MOR and β-M A N U S C R I P T 10 % foetal calf serum (FCS), 2 mM L-glutamine, 250 µg/ml hygromycin B (to select for tagged-β-arrestin expression) and 500 µg/ml G418 (to select for tagged-receptor expression). High titre (> 1 x 10 8 pfu/ml) P2 BacMam virus encoding GRK2 was generated by ThermoFisher, and cells were transduced in suspension at a multiplicity of infection of 5 immediately before seeding for assays.
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cAMP assay
MOR agonist G αi/o responses were investigated using the femto HTRF cAMP assay hours at 37 °C. DiscoverX detection reagent in lysis buffer was then added, and luminescence measured 1 hour later using an Envision plate-reader.
Membrane preparation
Cells were grown to 75-80 % confluence in 10 chamber 6360 cm 2 CellSTACK chambers (Corning) and dislodged using PBS wash and TrypLE. Cells were resuspended in ice-cold culture medium and washed with ice-cold PBS by centrifugation (1000 rpm, 5 minutes). Cells were then resuspended in ice-cold buffer (50 mM TRIS-HCl, 1 mM MgCl 2 , pH 7.4) and homogenized by 6 x 5 second blasts with an Ultra-Turax. Samples were then centrifuged (600 x g, 20 minutes, 4 °C), the supernatant collected and centrifuged again (55,000 x g, 45 minutes, 4 °C). Pelleted membranes were resuspended in buffer and samples homogenized using an Ultra-Turax. Protein concentration was determined using a Bradford assay with BSA as standards. Membranes were stored at -80 °C.
Radioligand binding
Methods were as previously described (Nickolls et al., 2013 
M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT
Page 11
RESULTS
Experimental strategy
We chose to study the MOR residues W320 and Y328, which as shown in Figure 1 are on the 7 th transmembrane helix of the receptor and protrude into the ligand binding pocket. W320 was mutated to A to remove the aromatic group of this residue, excluding the possibility for ligands to make any stacking or hydrogen-bond interactions. Y328 was mutated to F in order to maintain the aromatic moiety of this residue whilst removing the possibility to make hydrogen-bonds. The effect of each mutation was investigated by measuring the pharmacology of a panel of MOR ligands, constructing E/[A] curves for Pfizer standard-1, DAMGO, morphine, endomorphin-1, endomorphin-2, and metenkephalin. These were profiled in cAMP, β-arrestin2 and radioligand competition binding assays using the same cellular background. Pfizer standard-1 was chosen as a reference ligand for bias analyses because it was the only ligand to display sufficient activity in all the test systems to allow accurate curve-fitting analyses (and thus allowed for a simple comparison between all test systems).
The endogenous ligand would ordinarily be used as a reference, but complexity in the endogenous opioid system also precludes this choice. Bias was quantified by estimating the ligand transducer coefficients τ/K A at each pathway using the operational model agonism, and presented as ∆∆log(τ/K A )
values (see methods) (Black & Leff, 1983 ;Kenakin & Christopoulos, 2013). , which represents a significant loss of affinity at the mutants M A N U S C R I P T
Effect of mutation on expression and coupling levels
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Page 12 compared to the wildtype (ANOVA; < 0.05; n = 3). We also compared functional responses of these receptor species in the cAMP ( Figure 2B ) and β-arrestin2 ( Figure 2C ) assays using E/[A] curves with the full agonist Pfizer standard-1. Compared to MOR wildtype , E max in the cAMP assay was significantly reduced to 48.9 ± 13.6% for MOR W320A and 62.3 ± 10.0 % for MOR Y328F (ANOVA; P < 0.01; n = 5).
The loss of function in the β-arrestin2 assay was more severe, at 9.5 ± 0.9 % for MOR W320A and 10.3 ± 1.4% for MOR Y328F compared to MOR wildtype E max (ANOVA; P < 0.001; n = 5). Thus, whilst these mutations have little effect on receptor expression, there is a loss of signalling that is more extreme at β-arrestin2 than cAMP. We also measured basal signalling in the cAMP ( Figure 2D ) and β-arrestin2
( Figure 2E ) assays by treating parallel cells with vehicle, and found a modest significant loss of basal activity at MOR W320A in the cAMP assay (ANOVA; P < 0.05; n = 5) but no significant effect in the β-arrestin2 assays, and no effect in either assay at MOR Y328F .
Pathway bias at MOR wildtype
In cells expressing MOR wildtype , E/[A] analysis in both the cAMP ( Figure 3A ) and β-arrestin2 ( Figure   3B ) assays was performed for our ligand panel, with best-fit pEC 50 and E max values compiled in Table   1 . Whilst all agonists were fully efficacious in the cAMP assay, they were sub-maximal compared to
Pfizer standard-1 in the β-arrestin2 assay. In particular, morphine had low response maxima in the β-arrestin2 assay. Because the morphine E/[A] curve cannot be visualised when presented on the scale used to accommodate a full agonist, we have shown this data more clearly in Supplemental Figure 1 .
Each curve was analysed by calculating operational log(τ/K A ) estimates ( Figure 3C ; n = 5), and pathway bias was then estimated by comparing ligand responses to the reference agonist Pfizer standard-1 in order to cancel out the effect of observational/system bias. Differences in agonist activity at each pathway relative to the reference agonist were calculated as ∆log(τ/K A ) by subtracting log(τ/K A ) test agonist from log(τ/K A ) reference agonist . ∆∆log(τ/K A ) was calculated as ∆log(τ/K A ) β-arrestin2
subtracted from ∆log(τ/K A ) cAMP , and thus ∆∆log(τ/K A ) < 0 signifies cAMP bias, whilst > 0 signifies β-arrestin2 bias. This analysis ( Figure 3D ) indicated that relative to the reference agonist,
endmorphin-2 and met-enkephalin were cAMP-biased, whilst DAMGO, morphine, and endomorphin-1 showed no bias. These findings largely agree with cAMP vs. β-arrestin2 bias previously observed for MOR (Thompson et al., 2015) . . In summary, we observe ligand-specific directional changes in ligand bias at MOR W20A compared to MOR wildtype .
Pathway bias at MOR
Pathway bias at MOR Y328F
Parallel E/[A] analysis was also performed in cells expressing MOR
Y328F
, and normalized to Pfizer standard-1 response maxima in these cells ( Figure 5A , 5B and 5C; Table 3 ; n = 5). At MOR
, a M A N U S C R I P T . Using ∆∆log(τ/K A ) estimates ( Figure 5D ), we do not find any significant bias for the remaining compounds at MOR
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, although there was a trend towards cAMP bias for endomorphin-2 and met-enkephalin which is in line with their behaviour at the wildtype receptor.
Mutant bias calculations
Using the same data-set, we calculated mutant bias factors by directly comparing agonist activity between wildtype and mutated receptors within a single signalling pathway. For each ligand, ∆∆log(τ/K A ) was calculated by subtracting ∆log(τ/K A ) mutant from ∆log(τ/K A ) wildtype . Thus, ∆∆log(τ/K A ) > 0 signifies a gain in activity at the mutated receptor relative to the reference agonist , whilst < 0 signifies a loss of activity.
At MOR W320A ( Figure 6A ), DAMGO showed significant mutant bias, gaining relative activity in both cAMP and β-arrestin2 pathways compared to the wildtype (in relation to how the reference agonist behaved). Morphine and endomorphin-1 showed no significant preference for wildtype over mutant in the cAMP assay but were purely wildtype-biased in the β-arrestin2 assay owing to a lack of measureable efficacy in the mutant. In contrast, endmorphin-2 showed significant preference for the wildtype in the cAMP assay but showed no preference in the β-arrestin2 assay. A different pattern of change again was observed for met-enkephalin, which showed no preference in the cAMP assay but significant mutant bias in the β-arrestin2 assay. Rank order of E max from the agonist E/[A] curves can also be useful to understand bias, particularly when partial agonism is observed because the E max of a partial agonist is related to its efficacy. Figure   7C compares E max between receptor species at each pathway. In the β-arrestin assay, DAMGO shifts from partial agonism at MOR wildtyp e to full agonism at MOR W320A , again highlighting a selective gain of efficacy at this mutant. On the other hand, the drop in efficacy of DAMGO at MOR Y328F is signified by a drop in E max in the cAMP assay (and complete loss of efficacy in the β-arrestin2 assay). In contrast, endomorphin-2 gains E max in the β-arrestin assay at MOR Y328F compared to wildtype but drops E max in this assay in the MOR W320A system, whilst endomorphin-1 presents a more extreme example of this profile by having no observable efficacy in the MOR W320A β-arrestin2 experiments. In summary, comparing the pE 50 and E max estimates from E/[A] curves across each experimental M A N U S C R I P T
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Effect of MOR mutation on ligand binding affinity
The Table 4 . We analysed low affinity agonist binding (K L ) by the inclusion of GTP and sodium in the experimental system. The effect of mutation on affinity was represented as ∆∆pKi using Pfizer standard-1 as a reference (see methods), with a value > 0 signifying a gain in affinity at the mutant relative to Pfizer standard-1 and < 0 signifying a loss of affinity.
Affinity was lower for all the ligands at both MOR W320A and MOR Y328F compared to MOR wildtype .
However, when referenced to Pfizer standard-1 there was a significant gain in relative affinity at MOR W320A for DAMGO, morphine, endomorphin-1, and endomorphin-2, whilst met-enkephalin was unchanged (n = 4). There was no significant change in relative affinity at MOR Y328F for the ligands relative to Pfizer standard-1 ( Figure 6B ; n = 4), although there were trend towards a gain in affinity for morphine and endomorphin-1, and a loss of affinity for met-enkephalin.
Comparing affinity with function ( Figure 6 ) indicates a clear disconnect between mutation-mediated changes in binding and biased receptor activation. Not only can a mutation change function at the two pathways independently, but this can also occur independently of changes in binding affinity. For example, at MOR W320 endomorphin-2 gains relative affinity but loses activity at the cAMP pathway, but is unchanged at β-arrestin2, whilst endomorphin-1 and morphine gain relative affinity but selectively loose β-arrestin2 activity. At MOR Y328F the relative affinity of DAMGO is not changed but its activity at both pathways is lost. Therefore, the mutations do more than change ligand recognition, but can also qualitatively change how the receptor is activated after binding.
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Because the binding affinity of endomorphin-2 was least affected by mutation (Table 4) , we recalculated bias factors using this as the reference ligand (Supplemental Figure 2) . Although bias factors were somewhat different analysis (because we are setting a different arbitrary balance point of pathway activation), the ligand-specific mutation-driven changes in function were maintained.
GRK2 overexpression can rescue efficacy in the β-arrestin2 assay
To understand the role of assay sensitivity in limiting the observation of non-efficacious β-arrestin2
responses for some ligands, we investigated the effect of increasing the cellular expression of GPCR curves in GRK2 overexpressing cells. Endomorphin-1 ( Figure 8C ; n = 4), which has no detectable response at MOR W320A is rescued by GRK2, whilst at MOR Y328F it is a full agonist under control conditions and is further potentiated by GRK2. Conversely, DAMGO ( Figure 8D ; n = 4), which has no detectable response at MOR Y328F is rescued by GRK2, whilst at MOR W320A it is a full agonist under control conditions and is further potentiated by GRK2. Thus, GRK2 overexpression can rescue agonist β-arrestin2 responses that are lost with mutation, indicating that a lack of observed effect likely reflects low-level stimulation of this pathway that is otherwise below the detection limits of the assay rather than because of a complete lack of efficacy. This suggests that these agonists maintain affinity for the receptor active state even under circumstances when detection of efficacy is otherwise negligible, and that when the capacity for β-arrestin interactions is increased by GRK2 overexpression efficacy and potency are gained. Overexpression of GRK2 did not influence agonist potency or response maxima in the cAMP assay (Supplemental Figure 3) .
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Taking advantage of the ability of GRK2 overexpression to uncover responses of low efficacy ligands allowed us to now investigate bias of morphine at the mutated receptor. Using ∆log(τ/K A ) β-arrestin2 from GRK2 transduced cells ( Figure 8E ), we find that similarly to untransduced cells, morphine remains unbiased in the GRK2 overexpressed state. Bias factors of a larger panel of ligands are also minimally affected when using GRK2 overexpression to boost β-arrestin2 responses (Supplemental Figure 4) .
The mutations do not influence the bias of morphine remains unbiased at MOR W320A and MOR
Y328F
( Figure 8E ).
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DISCUSSION
There is a clear rationale for developing G i/o -biased MOR agonists; for improved analgesia and . Y328 corresponds to the classic class A GPCR orthosteric binding pocket, whilst W320 is located above this. Our data now suggest that beyond simply playing a role in ligand recognition, these residues are also critical in controlling how ligand binding interactions are translated to effector coupling and the generation of ligand bias. Clear differences in function and affinity between agonists were observed when these residues were mutated, indicating that ligandspecificity of docking interactions can lead to differences in how the receptor is activated. DAMGO and endomorphin-1 are the most striking examples of efficacy changes. DAMGO gained relative activity at both pathways when the W320A mutation was introduced, and there was a trend from lack of bias at the wildtype to β-arrestin2-bias at the mutant. DAMGO's behaviour was markedly different at the Y328F mutation as it lost activity in the cAMP assay and was completely non-responsive in the β-arrestin2 assay (unless cellular expression of GRK2 was boosted). In complete contrast, M A N U S C R I P T
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endomorphin-1 gained activity at both pathways at MOR Y328F , whilst it decreased cAMP activity and completely lost β-arrestin2 activity at MOR
W320A
. Endomorphin-2 is also an interesting example because we observe a directional shift in bias from cAMP preference at the wildtype receptor towards β-arrestin2 preference at MOR
, clearly highlighting the observation that bias can be dependent on a single amino acid change in the receptor.
Importantly, there was also a clear uncoupling between mutation-driven changes in pathway-selective activation and binding affinity ( Figure 6 ). For example, at MOR W320A endomorphin-1 lost function at both pathways despite a gain in relative affinity. Additionally, whilst receptor binding site expression levels did not change upon mutation, measured response magnitude was lost, with a far greater loss of coupling in the β-arrestin2 assay compared to cAMP (Figure 2 ). Together, these data suggest that observed changes in effector coupling are not necessarily just the outcome of perturbed ligand binding, but are instead linked to downstream events involved in receptor activation and transducer interactions and are a more complex representation of differences in receptor conformational dynamics. Therefore, the mutations can qualitatively change how the ligand activates the receptor once it is bound, underlining a role for the residues in forming active receptor conformations that otherwise dictate the balance of pathway activation of a given ligand.
Modelling MOR docking poses ( Figure 9 ) indicate differences between these ligands, from which we can begin to infer molecular mechanisms for our observations. Compared to DAMGO and Pfizer standard-1, endomorphin-1 interacts somewhat differently with the top of the binding cavity in the vicinity of the W320 residue. Interestingly, the analogous W 7.35 residue in the muscarinic M 2 receptor (W422) forms part of the "allosteric vestibule", sitting above the orthosteric binding site. Through mutagenesis and elegant studies using bespoke dualsteric probes to selectively manipulate the allosteric domain, it was previously shown that this region is involved in governing receptor activation and pathway bias between G protein and β-arrestin (Bock et al., 2012) . Moreover, the analogous 7.35 residues in the β2-adrenergic (Y308) and dopamine D2 (Y408) receptors have also been implicated in controlling ligand bias (Fowler et al., 2012; Woo et al., 2014) . These observations M A N U S C R I P T
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Page 21 have led to the hypothesis that dualsteric ligand binding can be important for ligand bias, where bitopic interactions with both orthosteric and allosteric receptor sites lead to allosteric restriction of conformational rearrangements, favouring activation of one effector pathway (Bock et al., 2014) .
Intriguingly, a recent molecular dynamics simulation has identified the involvement of W320 in an allosteric network of MOR (Bartuzi et al., 2016) , and this residue may also play a role discriminating between agonist and antagonist function (Fenalti et al., 2015) . Thus, ligand-specific interactions with W320 may offer an explanation for differentiation in receptor activation profiles and selective pathway engagement, as evidence by marked ligand-specific effects when this residue is mutated.
There is also precedent for a role of the Y 7.43 residue (Y328) in determing ligand bias at other receptors, with mutagenesis and modelling studies of the cholecystokinin-2 receptor implicating this residue in stabilizing the active receptor conformation for β-arrestin2 coupling (Magnan et al., 2013) .
Importantly, these, and our mutants provide convergent evidence that residues within the ligand binding pocket can influence qualitative aspects of receptor function, ultimately leading to biased signalling. We speculate that these regions may serve a common function in a number of GPCR subtypes, implying a wider applicability to our findings.
Through a better understanding of the molecular mechanisms of ligand bias, it is anticipated that we can begin to bridge the gap in our knowledge between how chemical information encoded within the molecular structure of a ligand is decoded into a pathway-selective receptor activation profile through the specific interactions it makes within the receptor binding site. Thus, by rationally designing novel compounds to interact in a predictable manner with MOR W320 and/or MOR Y328 (or equivalent in other receptors) we might improve the chance of successfully optimizing bias for pharmacotherapeutic benefit. Building up a larger profile of compound SAR at these mutants, alongside modelling their binding, could be a fruitful avenue to further peruse this goal. Pathway bias analysis showing ∆∆log(τ/K A ± 95 % CI from the data represented in C. * signifies no overlap of 95 % CI with zero (i.e. significant bias). "nd" signifies not determined due to sub-detection level responses. Open shapes represent "pure" cAMP bias because no effect could be measured in the β-arrestin2 assay, and are given a nominal ∆∆log(τ/K A ) value of -1. Table 4 . "nd"
signifies not determined due to sub-detection level responses. Table 1 . MOR wildtype data summary: best-fit pEC 50 and E max values (average ± STDEV of n = 5)
TABLES & TABLE LEGENDS
derived from E/[A] analysis in the cAMP and β-arrestin2 assays. Data from curves shown in Figure 3 . 
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